PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.28%
Some net income increase while AXSM is negative at -10.87%. John Neff would see a short-term edge over the struggling competitor.
720.76%
Some D&A expansion while AXSM is negative at -6.29%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Well above AXSM's 100.00% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-18.24%
Negative yoy SBC while AXSM is 255.81%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-114.66%
Negative yoy working capital usage while AXSM is 56.85%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-121.66%
Negative yoy AP while AXSM is 47.29%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
139.41%
Growth well above AXSM's 130.64%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-139.67%
Negative yoy while AXSM is 30.93%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-28.06%
Negative yoy CFO while AXSM is 3.01%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-383.87%
Both yoy lines negative, with AXSM at -100.00%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-383.87%
We reduce yoy invests while AXSM stands at 100.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-88.00%
Negative yoy issuance while AXSM is 180.03%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.